[company_age]2.0[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]Nodus Oncology is a biopharmaceutical company pioneering the development of next-generation therapies targeting the DNA damage response (DDR) pathway. Leveraging cutting-edge scientific advancements, Nodus Oncology is poised to revolutionize cancer treatment with its innovative portfolio of drugs. Founded through a collaboration between Cumulus Oncology and the Lead Discovery Center, the company is headquartered in Edinburgh, Scotland. Nodus Oncology's unwavering commitment to scientific excellence is evident in its focus on developing first-in-class and best-in-class molecules that inhibit novel DDR targets. These molecules hold immense promise in overcoming resistance mechanisms associated with existing therapies, offering new hope to cancer patients. Nodus Oncology's mission is to develop an innovative portfolio of drugs focused on synthetic lethality and collateral vulnerabilities in molecularly defined cancer patient populations. This targeted approach ensures that patients receive the most effective treatment possible, tailored to their specific needs. Nodus Oncology's unwavering dedication to scientific innovation and patient well-being positions it as a leader in the fight against cancer.[/description][ps]Nodus Oncology develops first-in-class and best-in-class molecules that inhibit novel targets within the DNA damage response (DDR) and replication stress response (RSR).[/ps]